anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A medical image archiving system, method, and storage medium are provided. The system may include at least an acquisition module, a storage module, and an archiving module. The acquisition module may be used to acquire a current medical image and archival instructions. The storage module can be used for storing a preset disease classification list, and the disease classification list comprises a plurality of disease classifications. The archiving module may be to archive the current medical image into a disease category in the list of disease categories based on the archiving instructions. The medical image filing system can be used for conveniently filing and collecting typical medical images by medical imaging doctors according to a preset disease classification list, and facilitates future review, sharing, scientific research and the like.
Observational studies have reported high comorbidity between obesity and severe COVID-19. The aim of this study is to explore whether genetic factors are involved in the co-occurrence of the two traits. Based on the available genome-wide association studies (GWAS) summary statistics, we explored the genetic correlation and performed cross-trait meta-analysis (CPASSOC) and colocalization analysis (COLOC) to detect pleiotropic single nucleotide polymorphisms (SNPs). At the genetic level, we obtained genes detected by Functional mapping and annotation (FUMA) and the Multi-marker Analysis of GenoMic Annotation (MAGMA). Potential functional genes were further investigated by summary-data-based Mendelian randomization (SMR). Finally, the casualty was identiied using the latent causal variable model (LCV). A significant positive genetic correlation was revealed between obesity and COVID-19. We found 331 shared genetic SNPs by CPASSOC and 13 shared risk loci by COLOC. At the genetic level, We obtained 3546 pleiotropic genes, among which 107 genes were found to be significantly expressed by SMR. Lastly, we observed these genes were mainly enriched in immune pathways and signaling transduction. These indings could provide new insights into the etiology of comorbidity and have implications for future therapeutic trial.
<P>PROBLEM TO BE SOLVED: To provide a solid powder cosmetic compounded with platy powder having an aspect ratio of as high as 10-400, enabling easy filling and forming of the cosmetic, having excellent impact resistance and smooth spreadability and giving finished skin having excellent lustering appearance (pearlescent feeling).  <P>SOLUTION: The solid powder cosmetic contains (A) 20-50 mass% platy powder of calcium sulfate dihydrate, (B) 40-70 mass% platy powder having an average particle diameter of 10-200 μm and an aspect ratio of 10-400 and (C) 2-10 mass% liquid oil. The platy powder of calcium sulfate dihydrate preferably has a major diameter of 30-100 μm, a minor diameter of 20-50 μm and a thickness of 1-3 μm. The cosmetic may further contain (D) 0.1-1.0 mass% solid oil powder insoluble to the oil of the component (C). The solid oil powder preferably has an average particle diameter of 0.05-20 μm and a melting point of 85-125°C.  <P>COPYRIGHT: (C)2010,JPO&INPIT
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: invention refers to biotechnology and immunology. Versions of a human CD37 specific antibody are presented, each containing a variable site of a light and heavy chain. A coding nucleic acid and a based expression vector are described. There are disclosed: a host cell containing a vector, a method of producing the antibody with using the cell, and also a composition for decreasing the B-cell count and a method of treating diseases associated with aberrant B-cell activity, with using the CD37-specific antibodies. ^ EFFECT: use of the invention provides specific loss of 80% BJAB cells at the antibody concentration 10 mcg/ml, and also increases the survival rate of Daudi mice as compared with Rhithuximab therapy that can find application for treating various tumours. ^ 39 cl, 39 dwg, 7 tbl, 18 ex
NEW MATERIAL:The galactostatin of formula, its derivative and their salt. USE:It is used as a galactosidase-inhibiting substance for the determination of galactosidase activity and is expected to be useful as a carcinostatic agent. It can be administered orally or parenterally to man and animal. It is extremely stable and hardly decomposable in acidic and neutral solution and has weak antibacterial and antiviral activities. PREPARATION:A microbial strain belonging to Streptomyces genus and capable of producing galactostatin is cultured aerobically in a nutrient medium, and the galactostatin of formula is separated from the culture product. The galactostatin can be converted to the lactam of formula (by the reaction with an oxidizing agent) or to the deoxy compound of formula (by the catalytic reduction in H2 stream with a catalyst such as PtO) which is an enzyme- inhibiting substance having strong inhibiting action to beta-galactosidase.
The present invention provides the use of gallic acid as an active ingredient for the manufacture of a composition for inhibiting symptoms caused by pollen. The subject of the invention is to inhibit symptoms caused by pollen. According to the "use of gallic acid as an active ingredient for producing a composition for inhibiting a symptom caused by pollen" of the present invention, the symptom caused by pollen is inhibited by allowing a subject to ingest gallic acid having substantially no antihistaminic activity. According to the application, various symptoms of pollen brought to people can be inhibited. Further, it is preferable that the subject ingests the composition in a range of 1mg to 20mg by the amount of gallic acid ingested per day. In addition, the subject preferably ingests the composition for more than 8 weeks.
BACKGROUND: Multiple debilitating symptoms and the progressive nature of Parkinson's disease (PD) affect carepartners' quality of life. Although, there is abundant knowledge on caregiver burden there is limited knowledge on PD carepartners' perceptions of caregiving.
AIM: To understand family members' perception of their role, and of the challenges and rewards of PD caregiving.
METHOD: Using a qualitative descriptive research design, we conducted semi-structured interviews with current and former PD carepartners (n = 16). Interviews were audio-recorded, de-identified, and transcribed verbatim. Data were coded and analyzed to identify themes.
RESULTS: We identified 5 themes: (a) Unpredictability is the hardest part of caregiving. It was hard to cope with the unpredictable daily and longer-term fluctuations in PD symptoms; (b) Disease progression and multiple symptoms contribute to carepartners' emotional distress. Carepartners felt unprepared and were saddened by the patient's and their own losses; (c) Caring for a family member is not a "burden." Though stressful, carepartners resisted associating caregiving with the term "burden"; (d) Caregiving is a partnership. Carepartners saw their role as being less of "givers" and more of partners in disease management; and (e) Caregiving is an opportunity for personal satisfaction, joy, and growth. Caregiving was seen as a "gift" that enabled carepartners to express love and experience personal growth.
CONCLUSIONS: Despite challenges PD carepartners view their role as "partners" in the management of the disease and find meaning and strength in caregiving. A palliative care approach emphasizing the positives and challenges of caregiving may provide carepartners with better support.
Chylous ascites is a rare form of ascites with high triglyceride content arising from the thoracoabdominal lymph nodes in the peritoneal cavity due to various benign or malignant etiologies, including pancreatic cancer. During cancer chemotherapy, the accumulation of ascites can lead to the deterioration of the patient's general condition, making chemotherapy administration difficult, and resulting in a poor prognosis. We encountered a rare case of chylous ascites complicated by advanced pancreatic cancer. The patient presented with a discrepancy between the shrinkage of the pancreatic cancer and the accumulation of ascites. Therefore, we were able to promptly diagnose chylous ascites by performing biochemical tests. The patient was treated with octreotide, reportedly effective in treating chylous ascites, which rapidly improved the chylous ascites and general condition of the patient, allowing the patient to continue chemotherapy for pancreatic cancer. Therefore, physicians should consider the possibility of chylous ascites when clinically unexplained ascites are observed in patients with advanced cancer. The investigation and treatment of chylous ascites should be initiated as soon as possible.
Traditionally, occupational therapists have utilized vibration for sensory re-education in compression neuropathies and peripheral nerve injuries. Vibration is also commonly used for desensitization of hypersensitivity following amputation, crush injury, and for hypersensitive scarring. Since the vibration tool is readily available in the hand therapy clinic, vibration analgesia should be further explored in the hand clinic to help reduce pain. Vibration is a simple, and non-invasive, tool and would be easy, economical, and practical to implement into the hand clinic for postoperative pain control. This research project will evaluate whether vibration can be a useful adjunct to current postoperative pain modalities. With a multidisciplinary approach, the investigators hope to highlight the use of non-opioid modalities of pain control in distal radius fractures and believe that the findings from this study may apply to other painful conditions of the hand as well.
Chronic kidney disease is a major public health problem, as population studies record a prevalence of 7.2% in individuals over 30 years and is expected to increase in the future. Many of them will end up undergoing hemodialysis treatment, and vascular access is not only an essential requirement for the technique, but also a determining factor in their prognosis; for all these reasons, every nephrologist should have both theoretical and practical knowledge of vascular access; however, the practical training is generally uneven and dependent on the hospital in which you train. It is within this context that the N-PATH (Nephrology Partnership for Advancing Technology in Healthcare) program was born with the objective of training 40 young European nephrologists in theoretical and practical aspects of Interventional Nephrology. To fulfill its mission, the 2-year program is composed of four modules of 6 months each including theoretical courses and hands-on training: Renal Expert in Molecular Pathology (REMAP), Renal Expert in Vascular Access (REVAC), Renal Expert in Medical Ultrasound (REMUS), and Renal Expert in Peritoneal Dialysis (REPED). By bringing together young nephrologists from all over Europe, the goal is also to create a strong network and promote Nephrology career at the European level. This publication highlights the experience of fellows who attended the REVAC hands-on training in Milan, focused on simulation and virtual reality for vascular access, and its impact on their nephrology training.
The invention relates to a preparation method, preparation and application of botanical tricin. The preparation method of the tricin comprises the following steps of: performing ultrasonic extraction on plant materials by aqueous or non-aqueous organic reagents used as solvents; filtering extract, performing reduced pressure distillation and recycling solvents to obtain total extract; performing chromatographic separation; combining identical components; and performing purification treatment to obtain fine tricin. The obtained tricin has high purity, and the content of the tricin can reach above 98 percent. The method has the advantages of simplicity, feasibility, short extraction time, low cost, high yield and low energy consumption and is suitable for industrial production. The obtained tricin can be prepared into various preparation formulations by a pharmaceutical method. Screening experiments of antitumor bio-activities prove that the tricin has significant curative effect on resisting tumors and can be applied to the preparation of antitumor medicaments or medicament compounds.
A novel alloy comprising bismuth and tin which is characterized by the co-presence of silver and/or antimony. Particularly described is a dental alloy comprising: 1. 30 to 74 weight percent bismuth 2. 19 to 69.9 weight percent tin 3. Either A. Silver in an amount of 0.1 to 5 weight percent; or B. Antimony in an amount of 0.1 to 7 weight percent; or C. Silver and antimony in a combined amount of 0.1 to 7 weight percent, the proportion of silver being not more than about 5% by weight.
The present invention relates to a soluble disinfecting condom. A soluble disinfecting condom is prepared by respectively dissolving dichlorophenyl biguanidinoethane as sterilizing and disinfecting medicine and nonoxynol as a spermatocide in the solution of polyvinyl alcohol, and then moulding and drying are carried out. By using the product of the present invention, dissolution only needs 2 to 3 minutes. The sterilizing and disinfecting medicine and the spermatocide are released and are uniformly distributed according to sexual activity. Viruses such as sperms, gonococci, etc. can be killed within 3 minutes. The present invention has contraceptive and medical functions, has positive actions for effectively executing plan procreation, and curing and preventing sexually transmitted diseases, and has good social benefit.
1,207,975. Bis - (acylamino - 2,4,6 - triiodobenzoic acid) - derivatives. PHARMACIA A.B. 12 Dec., 1967 [13 Dec., 1966], No. 56368/67. Heading C2C. [Also in Division A5] Novel compounds of the formula where R is C 1-5  carboxylic acyl and A is C 3-15  . alkylene substituted by one or more -O-R 1  groups, R 1  being H, C 1-5  alkyl or C 1-5  carboxylic acyl, and A being optionally broken by one or more oxygen bridges, or physiologically acceptable salts thereof, are obtained by reacting a compound of theformula or salt thereof with a compound of the formula Y.A.X (where each of Y and X is a halogen atom) or with a corresponding epoxide compound obtainable from Y.A.X by splitting off hydrogen halide, optionally treating the product with an alkylating or acylating agent and recovering the compound as such or in the form of a physiologically acceptable salt, such as the sodium or methylglucamine salts.
This is a randomized Phase III study comparing two doses of definitive radiation therapy given with induction and concurrent chemotherapy in HPV-positive oropharynx, unknown primary or nasopharynx cancer. Eligible, consented and registered patients will receive three cycles of Docetaxel Cisplatin and 5-FU (TPF) induction chemotherapy. After 3 cycles, the patients will be assessed for clinical, radiographic and pathologic response to TPF. Patients with a clinical or radiographic CR or PR will be randomized on the second phase of this study, where patients will undergo a 2:1 randomization to reduced (5600 cGy) or standard (7000 cGy) dose radiotherapy with weekly Carboplatin. Patients not meeting the response criteria will be treated with standard dose CRT. Patients not completing 3 cycles TPF for reasons of toxicity, progressive disease, choice, or other medical necessity will be treated with standard dose CRT or surgery depending on their primary site and overall medical condition and followed for survival. Toxicity will be assessed by Symptom scores, QOL and SAE monitoring. The primary end point of the trial is equivalent local regional control and PFS at 3 years. Patients will be followed for 5 years.
Do not use STAXYN in patients with moderate or severe hepatic impairment.

In volunteers with mild hepatic impairment (Child-Pugh A), the Cmax and AUC following a 10 mg vardenafil (film-coated tablets) dose were increased by 22% and 17%, respectively, compared to healthy control subjects. STAXYN can be used in patients with mild hepatic impairment. In volunteers with moderate hepatic impairment (Child-Pugh B), the Cmax and AUC following a 10 mg vardenafil (film-coated tablets) dose were increased by 130% and 160%, respectively, compared to healthy control subjects. Vardenafil has not been evaluated in patients with severe (Child-Pugh C) hepatic impairment. Do not use STAXYN in patients with moderate to severe hepatic impairment. [See Warnings and Precautions (5.8) and Dosage and Administration (2).]
BACKGROUND AND HYPOTHESIS: Acute kidney injury (AKI) could progress to chronic kidney disease (CKD) and the AKI-CKD transition has major clinical significance. A growing body of evidence has unveiled the role of pyroptosis in kidney injury. We postulate that GSDMD and GSDME exert cumulative effects on the AKI-CKD transition by modulating different cellular responses.
METHODS: We established an AKI-CKD transition model induced by folic acid in wildtype (WT), Gsdmd-/-, Gsdme-/-, and Gsdmd-/-Gsdme-/- mice. Tubular injury, renal fibrosis and inflammatory responses were evaluated. In vitro studies were conducted to investigate the interplay among tubular cells, neutrophils, and macrophages.
RESULTS: Double deletion of Gsdmd and Gsdme conferred heightened protection against AKI, mitigating inflammatory responses, including the formation of neutrophil extracellular traps (NETs), macrophage polarization and differentiation, and ultimately renal fibrosis, compared with wildtype mice and mice with single deletion of either Gsdmd or Gsdme. Gsdme, but not Gsdmd deficiency, shielded tubular cells from pyroptosis. GSDME-dependent tubular cell death stimulated NETs formation and prompted macrophage polarization towards a pro-inflammatory phenotype. Gsdmd deficiency suppressed NETs formation and subsequently hindered NETs-induced macrophage-to-myofibroblast transition (MMT).
CONCLUSION: GSDMD and GSDME collaborate to contribute to AKI and subsequent renal fibrosis induced by folic acid. Synchronous inhibition of GSDMD and GSDME could be an innovative therapeutic strategy for mitigating the AKI-CKD transition.
The invention discloses application of vesicles in preparation of tumor-targeted drug carriers, wherein the vesicles are derived from M1 type macrophages. Also disclosed is a medicament for treating tumors, characterized by comprising vesicles derived from M1 type macrophages, wherein the vesicles contain therapeutic drugs expressed by macrophages and/or targeting peptide tumor tissue targeting ingredients. The tumor therapeutic agent is expressed in macrophages and becomes entrapped within the vesicles when they are released. The macrophage surface expresses tumor tissue targeting molecule to make the vesicle with tumor tissue targeting. The vesicle is derived from M1 type macrophages with tumor treatment effect, so the vesicle also has certain tumor treatment characteristics. Experiments prove that the medicine carrier can be used for treating malignant tumors including breast cancer and colorectal cancer.
This is a prospective, non-randomized clinical trial in multiple stroke centres of China. The total sample size will be 200. Patients with anterior-circulation large artery occlusion obtaining successful recanalization after mechanical thrombectomy (MT) will be assigned into edaravone dexborneol or standard medication treatment group based on whether or not receiving edaravone dexborneol. Only patients with edaravone dexborneol initiating within 48 hours of stoke onset at 37.5 mg/dose, once every 12 hours, and continuing for more than 7 days could be enrolled as edaravone dexborneol group. Patients in standard medication treatment group must not receive edaravone dexborneol. Other neuroprotective agents are not limited to use.
PURPOSE: To evaluate the association between donor-related factors and the risk of rejection in patients undergoing penetrating keratoplasty (PKP) for keratoconus.
METHODS: A retrospective review was performed of keratoconus patients with no corneal neovascularization who underwent PKP from November 2014 to December 2016 and completed at least two years of follow-up. Preoperative, donor, operative, and postoperative data were collected and analyzed to identify factors leading to corneal graft rejection.
RESULTS: A total of 201 eyes (of 201 patients) that underwent PKP for keratoconus were included. Of these, 22.9% (95% CI 17.6-29.2%) had an episode of graft rejection. The overall graft survival rate was 98.5%. Receipts with a history of corneal transplant in the fellow eye (IRR 1.69, 95% CI 1.01, 2.80; p = 0.044) and those with postoperative stromal neovascularization (IRR 2.51, 95% CI 1.49, 4.21; p = 0.001) had a significantly higher incidence of rejection than those without these features. In univariate analysis, death-to-surgery time and death-to-excision time (DET) showed a weak association with graft rejection (p 0.05 and 0.08 respectively); However, in the multivariable analysis, this significance was lost. Grafts with a death-to-excision time (DET) greater than 8 h had a 0.53X lower risk of rejection compared with grafts with DET within 8 h or less (p = 0.05). Rejection was higher in patients receiving grafts with a preservation time within 7 days or less compared with preservation time greater than 7 days (30.6% vs. 21.2%, respectively, p = 0.291).
CONCLUSION: In the multivariable analysis, none of the donor-related factors were significantly associated with graft rejection; however, short death-to-surgery time may be associated with rejection after PKP. Recipients with a history of PKP in the fellow eye and those who developed corneal neovascularization were also at increased risk of developing rejection after keratoplasty.
PCT No. PCT/US89/00630 Sec. 371 Date Oct. 10, 1990 Sec. 102(e) Date Oct. 10, 1990 PCT Filed Feb. 15, 1989 PCT Pub. No. WO90/09165 PCT Pub. Date Aug. 23, 1990.A three component system and method for whitening teeth that comprises four primary active ingredients. The first component is a pre-conditioning mouth rinse comprised of a dilute aqueous solution of acetic acid and flavor enhancing additives. This component cleanses the pellicle film on the user's teeth. The second component is a bleaching gel including hydrogen peroxide. This gel also includes flavor enhancers, preservatives or surfactants necessary to formulate the gel. The preferred concentration of hydrogen peroxide is about six percent. The third component of the teeth whitening system is a polishing and pigmenting cream or paste that includes an abrasive substance and a pigmenting agent. The abrasive agent is preferably an alumina silicate and the pigmenting agent is preferably titanium dioxide particles. Flavor enhancers, a carrier, thickening agents, surfactants, preservatives and water are also to formulate the cream or paste. Methods of use formulation of the products are included.
PURPOSE:Thermostable-form microcrystals, consisting of microcrystals of 2-(2- dimethylaminobenzylsulfinyl)benzimidazole having a specific average particle diameter and decomposition point, having good stability and preservable as a medicine for a long period. CONSTITUTION:Microcrystals which are microcrystals of 2-(2- dimethylaminobenzylsulfinyl)benzimiazole, expressed by the formula and having <=10mu average particle diameter and 121-128 deg.C decomposition point. The microcrystals are produced by pulverizing crystals of the compound expressed by the formula to give <=10mu average particle diameter. A method for using a fluid energy micronizer as a pulverizer is preferred. The pulverizer is capable of pulling in compound particles to be micronized into a circuit by a violent gas stream and making the particles to collide with the circuit wall part, etc., to give fine particles. The particle diameter is preferably <=5mu.